Neurona lands $120m to advance regenerative cell therapy pipeline
Company’s cell therapy candidates target long-term repair of dysfunctional neural networks associated with conditions including Alzheimer’s.
San Francisco-based biotech company Neurona Therapeutics has raised $120 million in a funding round to advance regenerative cell therapy can…Read More

Sudo Bio lands additional $30m for TYK2 inhibitors with potential in Alzheimer’s
Dementia Discovery Fund joins new investors, citing Sudo’s potential in multiple neuroinflammatory diseases, including Alzheimer’s.
US biopharma Sudo Biosciences has raised an additional $30 million in the second round of its Series B financing, bringing the total…Read More

Researchers prevent memory deterioration in Alzheimer’s model
Research team at Tel Aviv University may have found way to predicting the disease in dormant state, before onset of cognitive decline.
Researchers at Tel Aviv University, in collaboration with the Safra Center for Neuroscience at the Hebrew University, have found ways to prevent a…Read More

Chrysea acquires Rodon to advance development of nutritional longevity products
Juvenescence-backed biotech snaps up biomanufacturing firm to enhance its synthetic biology and biopharma development capabilities.
Longevity nutrition biotech Chrysea has acquired biomanufacturing firm Rodon Biologics from Iberfar Group for an undisclosed amount.…Read More

Vaxxinity’s cholesterol vaccine reduces LDL in primates
Promising preclinical results for cholesterol vaccine candidate boost hopes for treatment and prevention of heart disease.
Immunotherapeutic vaccine developer Vaxxinity has published promising preclinical data for its cholesterol vaccine candidate, VXX-401. The findings, published in the J…Read More

Rejuvenate Bio makes progress on osteoarthritis gene therapy for dogs
Gene therapy company inks strategic partnership with animal health firm to develop ‘one-dose’ injection treatment for canine osteoarthritis.
Longevity biotech company Rejuvenate Bio has revealed a strategic partnership to advance the development and commercialization of its…Read More

Bioptimus primed with $35m to unravel disease biology using AI
French startup founded by former Google DeepMind talent aims to build first ‘universal AI foundation model’ for biology.
Paris-based AI startup Bioptimus has emerged from stealth, securing seed funding of $35 million to advance its mission to generate computational rep…Read More

Rejuvenate Biomed reveals promising efficacy results in sarcopenia trial
Combination of metformin and galantamine demonstrates ‘meaningful improvements’ in muscle strength, function and fatigue resistance.
Longevity biotech Rejuvenate Biomed has revealed functional outcome results from the recent Phase 1b trial of its lead drug in patients wit…Read More

AI-discovered drug for ALS enters clinical trials
Patient enrollment complete for clinical trial of 4B Technologies’ AI-discovered ALS drug supported by Insilico Medicine.
Patient enrollment complete for clinical trial of 4B Technologies’ AI-discovered ALS drug supported by Insilico Medicine.
Two years after the collaboration was announced bet…Read More

Rejuvenate Bio shows epigenetic reprogramming extends lifespan in normal mice

Rejuvenate Bio shows epigenetic reprogramming extends lifespan in normal mice

New paper first to show that gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged wild mice.
Longevity…Read More